Back to Authors

Guan, Xuesong

A5103833180 | I180857899

Mayo Clinic

Pfizer (United States)

Citations 1

MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer

Future Oncology | December 26, 2024 | Volume: 21 | Issue: 3 | Pages: 303-311

10.1080/14796694.2024.2441101 | PMID 39723627